A prospective drug for Alzheimer’s disease that failed to show efficacy in late 2017 based on a Bayesian analysis of patient data, has now demonstrated its promise using more conventional statistical methods, according to Eisai Co Ltd and Biogen Inc.
The drug, BAN2401, is a monoclonal antibody targeting beta-amyloid, protein fragments in the brain which are thought to contribute to the neurodegenerative process in Alzheimer’s disease.